New treatments for melanoma and cervical cancer were cited as the most important subjects of new clinical information presented at the 2013 ASCO Annual Meerting, according to the second annual ASCO Impact Report released recently by Encuity Research. New treatments for melanoma, with an emphasis on PD-1 treatments, were cited by 31% of respondents, while advances in the treatment of cervical cancer were cited by 20% of respondents, as the most important new clinical information at the meeting.
Annual Meeting Reported as Valuable
The ASCO Impact Report is based on a survey of 100 oncologists who attended the 2013 ASCO Annual Meeting and is designed to gauge physician perceptions about the Annual Meeting and its effect on clinical practice. Respondents to the survey found ASCO to be valuable overall, with half of physicians having rated the event as very or extremely valuable, and 86% reporting that this year’s Annual Meeting was equal to or more valuable than the 2012 Annual Meeting.
The ASCO Impact Report provides an encompassing view of ASCO attendees’ intent to change treatment plans and their perceptions of clinical information presented. Their ratings of information offered by pharmaceutical and biotech companies are also measured.
For more information and to download a copy of the ASCO Impact Report, visit http://www.encuity.com/ASCO. ■
